[ { "id": 1696, "name": "Forever Labs", "slug": "forever-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/2551f858875b49e48688473a8dad17ee8425d618.png", "website": "https://foreverlabs.com", "all_locations": "Ann Arbor, MI, USA", "long_description": "Forever Labs collects and stores adult stem cells, and develops therapies based upon stem cell rejuvenation.", "one_liner": "We bank your stem cells to help you live healthier, longer.", "team_size": 12, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1495941669, "tags": [ "Anti-Aging" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/forever-labs", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/forever-labs.json", "year_founded": 2015, "city": "Ann Arbor", "country": "US", "linkedin_url": "https://www.linkedin.com/company/forever-labs-inc/", "x_url": "https://twitter.com/ForeverLabsInc", "fb_url": "https://www.facebook.com/bankwithforeverlabs/", "cb_url": "https://www.crunchbase.com/organization/forever-labs", "github_url": "https://github.com/ForeverLabs", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/2551f858875b49e48688473a8dad17ee8425d618.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 198081, "full_name": "Steven Clausnitzer", "title": "Founder/CEO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/steven-clausnitzer-5142bb127/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/6d7d0897b17911876eeb8f4bad897ddfbae566e2.jpg" }, { "user_id": 198150, "full_name": "Edward Cibor", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": null, "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c7438154682ed002bdcb5997cc003b2f0c7ca0b7.jpg" }, { "user_id": 49067, "full_name": "Mark Katakowski", "title": "Founder/President & Chief Science Officer", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/mark-katakowski-4a626b127/", "x_url": "https://twitter.com/markkatakowski", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/8129e65168647c3d09fcc5b5a6b3fa7b645472a8.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 2016, "name": "dNovo", "slug": "dnovo", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/22ea7b2ff1e1af9ded028f1c3a9d1ad91f17021f.png", "website": "http://dnovobio.com/", "all_locations": "San Francisco, CA, USA; San Jose, CA, USA", "long_description": "At dNovo, we are curing hair loss by creating new hair, de novo. We are doing this with cellular reprogramming technology that we pioneered at Stanford and Harvard. With this technology, we can take any patient derived cell, whether it be blood, skin or fat and reprogram (convert) them into medically relevant cell types. Our first objective is to cure hair loss by using our reprogramming technology to make new hair (patent pending). This is different from everything currently available on the market because the hair loss industry is focused on maintaining the hair that you already have, but no one is trying to produce NEW hair, de novo. After hair, we envision using our cellular reprogramming technique to make any cell, any tissue or any organ on demand to replace what is lost as we age.", "one_liner": "The cure for hair loss.", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1635867695, "tags": [ "Anti-Aging" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Inactive", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/dnovo", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/dnovo.json", "year_founded": 2018, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/22ea7b2ff1e1af9ded028f1c3a9d1ad91f17021f.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 250632, "full_name": "Ernesto Lujan", "title": "Founder", "founder_bio": "Ernesto Lujan received his Ph.D. in Genetics from Stanford, and has published cutting edge research on regenerative medicine in Nature, Cell Stem Cell, and the Proceedings of the National Academy of Sciences. His discovery of directly reprogramming skin into neural stem cells that successfully integrated in a live mouse brain was featured in the BBC. He has received awards from the National Science Foundation, Ford Foundation, and California Institute for Regenerative Medicine. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/ernesto-lujan-782469b9", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/f6eb0e854dabcca2d0e13e2152b26b69d18c5177.jpg" } ], "jobs": [], "news": [ { "title": "Hope for your hairline may be coming as biotech startups try to reverse balding | Fortune", "url": "https://fortune.com/2022/01/18/hope-for-your-hairline-may-be-coming-as-biotech-startups-try-to-reverse-balding/", "date": "Feb 07, 2022" } ], "launches": [] }, { "id": 2027, "name": "Dorian Therapeutics", "slug": "dorian-therapeutics", "former_names": [ "Dorian therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e2ba869954327a53b835f8f98ae03cf923b67fa1.png", "website": "http://www.doriantherapeutics.com", "all_locations": "San Francisco, CA, USA; San Carlos, CA, USA", "long_description": "", "one_liner": "New therapeutics to rejuvenate tissue and treat age-related diseases ", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527534657, "tags": [ "Anti-Aging", "Biotech", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Acquired", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/dorian-therapeutics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/dorian-therapeutics.json", "year_founded": 2018, "city": "San Francisco", "country": "US", "linkedin_url": "http://www.linkedin.com/company/doriantx", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/e2ba869954327a53b835f8f98ae03cf923b67fa1.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 261263, "full_name": "Maddalena Adorno", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "linkedin.com/in/adornomaddalena", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/3397ba70f7ec0a6795de85051d1da29ba833e0c7.jpg" }, { "user_id": 261540, "full_name": "Benedetta di Robilant", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/benedetta-di-robilant-a196ba15/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/da0498b09a6d009d4d9e0dfe14223c21bb2b17ba.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 2028, "name": "Rejuvenation Technologies Inc.", "slug": "rejuvenation-technologies-inc", "former_names": [ "Rejuvenation Technologies Inc.", "Rejuvenation Technologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/8570f907143e200c57848585eb12a16271d3643f.png", "website": "https://www.rejuvenationtech.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months. ", "one_liner": "mRNA therapeutics to extend healthspan entering clinical trials", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527534662, "tags": [ "Anti-Aging", "Gene Therapy", "Nanomedicine" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/rejuvenation-technologies-inc", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/rejuvenation-technologies-inc.json", "year_founded": 2016, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/8570f907143e200c57848585eb12a16271d3643f.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 258817, "full_name": "Glenn Markov", "title": "Founder", "founder_bio": "Stanford PhD Genetics (2018)", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/glennmarkov/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a56bc931d6209b5b6271761fac6314f084d0bdbe.jpg" }, { "user_id": 257342, "full_name": "John Ramunas", "title": "Founder", "founder_bio": "John Ramunas, PhD, invented TERT mRNA telomere extension at Stanford in Helen Blau's lab — reversing a decade of telomere shortening in one treatment. 50+ granted patents across 7 families through 2046. Preclinical efficacy in 4 organ systems. FDA INTERACT cleared. Khosla Ventures seed. YC S18. Raising $10M seed extension ($2M wired) for 3 clinical trials — Phase I readout Q3 2027. Subject #1 in first human trial.", "is_active": true, "linkedin_url": "https://linkedin.com/in/johnramunas", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/78c9daa6b85e2b4ccd29f05dd92ac1f3dfb0f9b2.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 22659, "name": "Lygg", "slug": "lygg", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ad3874f6bb8a88d69390c4e1ea06a028d9d21835.png", "website": "http://www.lyggcorp.com", "all_locations": "San Francisco, CA, USA", "long_description": "Up to 90% of skin aging is caused by UV light from the sun. Most of this is caused by UVA light and only two FDA-approved chemical ingredients protect against it, one of which is neither photostable nor GRASE. To address this, we have developed a patented, photostable, and safe ingredient that can dramatically increase current UVA protection.", "one_liner": "Building New Anti-Aging Ingredients for Skincare", "team_size": 1, "industry": "Consumer", "subindustry": "Consumer -> Apparel and Cosmetics", "launched_at": 1648234214, "tags": [ "Anti-Aging", "Beauty" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Consumer", "Apparel and Cosmetics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/lygg", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2021/lygg.json", "year_founded": 2020, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/lygg", "x_url": "https://twitter.com/LyggCorp", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/lygg", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ad3874f6bb8a88d69390c4e1ea06a028d9d21835.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 477773, "full_name": "Graham Dick", "title": "Founder", "founder_bio": "Graham Dick is the CEO and co-founder of Lygg. Originally from Vancouver, Canada, Graham obtained his PhD in Chemistry from Stanford University and previously served as a postdoctoral researcher at EPFL in Lausanne, Switzerland. Following the ban of two common sunscreen ingredients in Hawaii and due to increasing concerns regarding the skin penetration of the remaining ingredients, Graham founded Lygg in 2020 to create a new generation of safe, innovative sunscreen ingredients.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/grahamrdick/", "x_url": "https://twitter.com/grahamrdick", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e61c789a6696b16b359ebee39ccf10aecbce5bb6.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 23264, "name": "Eat Blueprint", "slug": "eat-blueprint", "former_names": [ "Athens Research" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4aa01acb5da85aa65e3b1d4de9d3719618e25261.png", "website": "https://eatblueprint.com", "all_locations": "San Francisco, CA, USA; Remote", "long_description": "Making Blueprint Protocol-inspired meals for longevity and performance. Organic, local, gluten-free, and seed oil free.", "one_liner": "Longevity Nutrition Service", "team_size": 2, "industry": "Consumer", "subindustry": "Consumer -> Food and Beverage", "launched_at": 1614368026, "tags": [ "Anti-Aging", "Fitness", "Food", "Health & Wellness", "Food & Beverage" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Inactive", "industries": [ "Consumer", "Food and Beverage" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/eat-blueprint", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2021/eat-blueprint.json", "year_founded": 2020, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/4aa01acb5da85aa65e3b1d4de9d3719618e25261.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 202784, "full_name": "Jeff Tang", "title": "Founder", "founder_bio": "Founder of Athens Research (W21), an open-source networked note-taking app.\nPivoted to Eat Blueprint, acquired by Bryan Johnson / Blueprint Protocol.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/jefftangx/", "x_url": "https://x.com/jefftangx", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/4c770b3b6bea66c22f50c0ad944614e8ddd6e71f.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 24795, "name": "SFA Therapeutics", "slug": "sfa-therapeutics-inc", "former_names": [ "SFA Therapeutics, Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5873834b208e59808a81e6f7b65403be4dd9fc78.png", "website": "https://sfatherapeutics.com/", "all_locations": "Philadelphia, PA, USA", "long_description": "SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.", "one_liner": "Regulating the immune system to block cancer & autoimmune diseases", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1624038758, "tags": [ "AI-powered Drug Discovery", "Anti-Aging", "Biotech", "Health & Wellness", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": true, "app_answers": [ { "question": "What is your company going to make? Please describe your product and what it does or will do.", "answer": "SFA Therapeutics, Inc is a biotech with a novel immunomodulatory platform that is focused on the intersection of NF-kB and Ras in the treatment of chronic inflammatory diseases and oncogenesis (the onset of cancer), respectively.\r\n\r\nOur vision is to change the practice of Medicine by treating chronic inflammatory conditions that result in cancer, such as hepatitis, which progresses to liver cancer, and pancreatitis, which progresses to pancreatic cancer, by blocking the primary inflammatory pathways with our discoveries..\r\n\r\nSFA is developing small molecule drugs originally derived from human GI bacterial metabolites, which have been shown to modulate the immune system through a complex cascade that affects several important molecular pathways, ultimately downregulating NF-kB and RAS, which control involved in inflammation and carcinogenesis. This platform has led to the development of six drugs to treat immuno-inflammatory diseases, using psoriasis as a proof-of concept for autoimmune diseases and chronic liver diseases that are caused by inflammation, including Hepatitis B virus-mediated chronic liver disease, NASH and Hepatocellular Carcinoma (HCC), the most common form of liver cancer. SFA’s two most advanced assets are SFA001 and SFA002, for liver disease and autoimmune diseases, respectively. SFA002 has an approved IND and is ready to enter into clinical trials in patients.\r\n\r\nOur plan is to develop these drugs through phase 2 and create phase 3-ready assets, to license to pharma and biotech partners, in exchange for license fees, royalties and milestone payments." } ], "question_answers": [ { "question": "What is the core problem you are solving? Why is this a big problem? What made you decide to work on it?", "answer": "**A completely new approach to treating autoimmune disease, by treating the underlying disease instead of suppressing the immune system.**" }, { "question": "What is your long-term vision? If you truly succeed, what will be different about the world?", "answer": "**Functional cures for autoimmune diseases**" } ], "url": "https://www.ycombinator.com/companies/sfa-therapeutics-inc", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/sfa-therapeutics-inc.json", "year_founded": 2016, "city": "Philadelphia", "country": "US", "linkedin_url": "https://www.linkedin.com/company/sfa-therapeutics/", "x_url": "http://twitter.com/@sfatherapeutics", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/5873834b208e59808a81e6f7b65403be4dd9fc78.png", "app_video_url": null, "dday_video_url": "https://bookface-images.s3.us-west-2.amazonaws.com/video_event/54/1630622959176-jk4w3wwvw0d-f58b3002cf397d2525b1bb3d6d1730f5/a59a8aa25f19cd002185361ca819f8f1.mp4?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAQC4NIECABPQ2AHNW%2F20261020%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20261020T022700Z&X-Amz-Expires=3600&X-Amz-SignedHeaders=host&X-Amz-Signature=1a82d296f6033595c026decfb74b9b1415c1ae3edfd3026b91f734a2409882a6", "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 470235, "full_name": "Ira Spector", "title": "Founder", "founder_bio": "Dr. Spector is the co-founder of SFA, a microbiome-derived pharmaceutical company focused on new advancements in the treatment inflammatory diseases. An experienced drug developer with over 30 years of experience, he helped develop 34 drugs and 12 medical devices, including Enbrel, Effexor, Protonix, Prevenar, Ozurdex, Botox for Overactive Bladder, Chronic Migraine and Cerebral Palsy. He holds BS degrees in Physics and EE from Washington University, an MBA from Drexel, and a PhD from Rutgers.\n", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/ira-spector-00414310/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/8d17c573b2d929f75bf6ca2e9f4e2cb586e95cd7.jpg" }, { "user_id": 475228, "full_name": "Alla Arzumanyan", "title": "Founder", "founder_bio": "MS is Microbiology,\nPhD in Biotechnology,\nAssistant Professor at Temple University,\nCo-Founder and Co-Inventor at SFA Therapeutics, Inc.\nPerformed a case-control, Proof-of-Activity Human study to evaluate treatment effect of SFA002 drug (proprietary of SFA Therapeutics, Inc.) on patients with plaque psoriasis.\nWorked with Axella Research on pre-IND application for SFA002.\nWorked with HEC (Sunshine Lake Pharma Co., China), Theravectys, and ThirdLaw LLC (still collaborating with the latter)", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/alla-arzumanyan-66a79a18b", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c53d726559d2b7621f20dc5e8b2195b813db97fc.jpg" }, { "user_id": 475711, "full_name": "Mark Feitelson", "title": "Founder", "founder_bio": "Mark Feitelson received his Ph.D. in Microbiology/Immunology from UCLA. He began his work with hepatitis B at Stanford University, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). In 1991, Dr. Feitelson moved to Thomas Jefferson University, and in 2007, to Temple University as a Professor of Biology. His work has been supported by NIH, industry and foundations. He has more than 150 publications and 180 abstracts. He is also CSO of SFA Therapeutics. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/mark-feitelson-707771a", "x_url": "https://twitter.com/feitelson", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/3192ca2979c1fea02c4df51becafcb0e76d2b53d.jpg" } ], "jobs": [], "news": [ { "title": "SFA Therapeutics Announces Updated Psoriasis Data", "url": "https://www.globenewswire.com/news-release/2023/11/09/2777360/0/en/SFA-Therapeutics-Announces-Updated-Psoriasis-Data-for-SFA-002-Bridge-Financing-and-Foundational-Patent.html", "date": "Nov 09, 2023" }, { "title": "SFA Therapeutics announces results for SFA-002 from Phase", "url": "https://www.globenewswire.com/en/news-release/2023/08/14/2724489/0/en/SFA-Therapeutics-announces-results-for-SFA-002-from-Phase-1b-Cohort-1-clinical-trial-for-treatment-of-mild-to-moderate-psoriasis.html", "date": "Aug 14, 2023" }, { "title": "Short-chain fatty acids in cancer pathogenesis | Cancer and Metastasis Reviews", "url": "https://link.springer.com/article/10.1007/s10555-023-10117-y#Fun", "date": "Jul 11, 2023" }, { "title": "Treat Disease, Not the Symptoms", "url": "https://www.appliedclinicaltrialsonline.com/view/treat-disease-not-the-symptoms", "date": "Mar 07, 2023" }, { "title": "A biotech CEO’s favorite ‘F’ word At SFA Therapeutics, patients are the “focus” ", "url": "https://sfatherapeutics.com/sfa-therapeutics-ceo-ira-spector-profiled-in-pharmavoice/", "date": "Jan 26, 2023" } ], "launches": [] } ]